Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172) (original) (raw)

A phase I/II trial investigated the efficacy and safety of Mycobacterium vaccae (SRL172) as an immunotherapy for patients with advanced hormone-refractory prostate cancer. Ten patients received SRL172 injections, with serum prostate-specific antigen (PSA) levels monitored as a response marker. Results indicated a decline in PSA levels for two patients, along with cytokine profile changes, suggesting a shift from a predominantly Th2 to Th1 response in some cases. These findings highlight the potential of SRL172 as an immunotherapeutic agent, warranting further investigation in randomized trials.